Pharmacotherapy in benign prostatic enlargement
the impact of tamsulosin and dutasteride on erectile dysfunction
DOI:
https://doi.org/10.59736/IJP.23.04.1024Keywords:
Benign Prostatic Hyperplasia, Combination Therapy, Dutasteride, Erectile Dysfunction, TamsulosinAbstract
Background: Benign prostatic enlargement (BPE) becomes increasingly common as men grow older. A wide range of lower urinary tract symptoms (LUTS)occur as the condition progresses. Erectile dysfunction (ED) frequently coexists with these symptoms and may be influenced by the medications used to treat BPE. This study compared the impact of tamsulosin alone with that of the tamsulosin–dutasteride combination on erectile function.
Methods: This multicenter cross-sectional study was conducted in the urology and surgical outpatient clinics of two hospitals. A total of 79 sexually active men over the age of 50 with LUTS related to BPE were included. Participants were divided into two groups: Group A (n=41), receiving tamsulosin 0.4 mg daily, and Group B (n=38), receiving a fixed-dose combination of tamsulosin and dutasteride. Erectile function was evaluated using the Sexual Health Inventory for Men (SHIM), a validated questionnaire.
Results: In the present study, erectile-function outcomes were closely examined in men treated either with tamsulosin alone or with a tamsulosin–dutasteride combination. When SHIM scores were compared between the two groups, the averages were nearly the same (14.8 ± 6.6 for men receiving tamsulosin only, and 15.7 ± 5.2 for those on the combined regimen; p = 0.48). A similar pattern appeared when erectile-dysfunction severity was analyzed across standard categories (p = 0.62). Erectile dysfunction was widespread in both groups, and the distribution of age and major comorbidities were well balanced at baseline.
Conclusion: These results indicate that LUTS/BPH, is likely the primary contributor to sexual difficulties, rather than the specific medication prescribed. These findings can help guide patient counseling, reassuring them that the choice between these common regimens, based on prostate size and symptom severity, may not confer an additional risk to erectile function specifically.
References
Memon AH, Chandio MA, Bhellar ZH, Rehman HU, Akhtar S, Bhurt A. Role of uroflowmetry in patients of benign prostatic hyperplasia presenting with lower urinary tract symptoms: uroflowmetry in benign prostatic hyperplasia. Pak J Health Sci. 2024 Nov;5(11):40–5. doi:10.54393/pjhs. v5i11.2409.
Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61(2):267-73. doi:10.1016/S0090-4295(02)02371-3.
McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005 Jun;47(6):838-45. doi: 10.1016/j.eururo.2005.02.001.
Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007 Oct;26(S6):928-33. doi:10.1002/nau.20485.
Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules. 2021 Nov;26(23):7141. doi:10.3390/molecules26237141.
Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.03.002.
Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms. Arnhem, The Netherlands: European Association of Urology; 2023. doi:10.1016/j.eururo.2023.04.008.
Trost L, Saitz TR, Hellstrom WJ. Side effects of 5-alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013 May;1(1):24-41. doi:10.1002/smrj.3.
Carlucci M, Cito G, Cocci A, Rizzo M, Gontero P, Russo GI, et al. Sexual dysfunction during 5α-reductase inhibitor therapy: a comprehensive review. Aging Male. 2018 Dec;21(4):243-50. doi:10.1111/andr.12353.
Roehrborn CG, Manyak MJ, Palacios‐Moreno JM, Wilson TH, Roos EP, Santos JC, et al. A prospective randomised placebo‐controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018 Apr;121(4):647-58. doi:10.1111/bju.14057.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and validation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319–26. doi: 10.1038/sj.ijir.3900472.
Zhou Z, Cui Y, Wu J, Zhang M, Wang Y, Li H, et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019; 19:17. doi:10.1186/s12894-019-0446-8.
Ali SM, Asim M, Murtaza Y, Ahmed SF, Memon W, Rashid M, et al. Efficacy of combination therapy with alpha-1 blocker and 5-phosphodiesterase inhibitor in patients with benign prostatic hyperplasia associated lower urinary tract symptoms (LUTS). Pak J Med Health Sci. 2022 Mar;16(2):569-72.
Dimitropoulos K, Gravas S. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol. 2016 Feb;8(1):19-28. doi: 10.1177/1756287215607419.
Amani B, Davari M, Amani B, Akbarzadeh A, Shabestan R. Combination therapy with Tamsulosin plus Dutasteride Versus Tamsulosin in Benign Prostatic Hyperplasia: a Systematic review & Meta-analysis. J Pharmacoecon Pharmacomanag. 2022;8(4):7-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Muddasir Sajjad, Hamza Ashraf, Talat Shahzad, Nadir Saifullah Khan, Maryam Imran, Naveed Ahmad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
